Loading company…
Senseonics develops implantable continuous glucose monitoring systems for diabetes management.
Senseonics develops continuous glucose monitoring technology for people with diabetes. Its Eversense system is implanted in the upper arm and monitors glucose for up to 90 days, with readings available through a mobile app. Founded in 2015, the company is based in Germantown, US, and serves patients and healthcare providers. In 2022, it reported revenue of USD 16.39 mn and EBITDA of USD -67.64 mn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in